Chinook Therapeutics, Inc.
- Country
- 🇨🇦Canada
- Ownership
- Public, Subsidiary
- Established
- 2019-01-01
- Employees
- 214
- Market Cap
- -
- Website
- http://ww.chinooktx.com
A Study of BION-1301 in Adults With IgA Nephropathy
- Conditions
- Interventions
- First Posted Date
- 2023-05-10
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Chinook Therapeutics, Inc.
- Target Recruit Count
- 292
- Registration Number
- NCT05852938
- Locations
- 🇺🇸
University of Alabama at Birmingham: The Kirklin Clinic, Birmingham, Alabama, United States
🇺🇸Intermed Consultants, Edina, Minnesota, United States
🇺🇸University of Cincinnati College of Medicine - 231 Albert Sabin Way, Cincinnati, Ohio, United States
Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy
- Conditions
- Interventions
- First Posted Date
- 2023-04-28
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- Chinook Therapeutics, Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT05834738
- Locations
- 🇺🇸
University of Alabama at Birmingham (UAB) - The Kirklin Clinic (TKC) - Nephrology Clinic, Birmingham, Alabama, United States
🇺🇸Fides Clinical Research, Atlanta, Georgia, United States
🇺🇸NANI Research, Oak Brook, Illinois, United States
Open-label Safety and PK Study of BION-1301 in Japanese Healthy Subjects
- First Posted Date
- 2022-08-19
- Last Posted Date
- 2023-01-11
- Lead Sponsor
- Chinook Therapeutics, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT05508204
- Locations
- 🇺🇸
Collaborative Neuroscience Research, LLC, Long Beach, California, United States
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CHK-336 in Healthy Volunteers
- First Posted Date
- 2022-05-10
- Last Posted Date
- 2023-11-03
- Lead Sponsor
- Chinook Therapeutics, Inc.
- Target Recruit Count
- 88
- Registration Number
- NCT05367661
- Locations
- 🇺🇸
Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States
Atrasentan in Patients With IgA Nephropathy
- Conditions
- Interventions
- First Posted Date
- 2020-10-05
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- Chinook Therapeutics, Inc.
- Target Recruit Count
- 404
- Registration Number
- NCT04573478
- Locations
- 🇺🇸
Liberty Research Center, Dallas, Texas, United States
🇨🇳The First Affiliated Hospital of Fujian Medical University, Fuzhou, China
🇨🇳Peking University People's Hospital, Beijing, China
Atrasentan in Patients With Proteinuric Glomerular Diseases
- Conditions
- Interventions
- First Posted Date
- 2020-10-05
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Chinook Therapeutics, Inc.
- Target Recruit Count
- 103
- Registration Number
- NCT04573920
- Locations
- 🇬🇧
Royal Hospital London, London, England, United Kingdom
🇦🇺Monash Health- Monash Medical Centre, Clayton, Victoria, Australia
🇺🇸Academic Medical Research Institute, Los Angeles, California, United States
Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN)
- Conditions
- Interventions
- First Posted Date
- 2019-05-10
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Chinook Therapeutics, Inc.
- Target Recruit Count
- 103
- Registration Number
- NCT03945318
- Locations
- 🇺🇸
Chris Sholer, P.C., Oklahoma City, Oklahoma, United States
🇺🇸Amicis Research Center, Northridge, California, United States
🇺🇸New York Nephrology, Clifton Park, New York, United States
Safety and Tolerability of BION-1301 in Adults With Relapsed or Refractory Multiple Myeloma (MM)
- First Posted Date
- 2017-11-14
- Last Posted Date
- 2021-04-01
- Lead Sponsor
- Chinook Therapeutics, Inc.
- Target Recruit Count
- 21
- Registration Number
- NCT03340883
- Locations
- 🇺🇸
James R. Berenson, MD, Inc, West Hollywood, California, United States
🇺🇸Winship Cancer Institute/Emory University, Atlanta, Georgia, United States
🇺🇸Ohio State University Wexner Medical Center James Cancer Hospital, Columbus, Ohio, United States